This segment focuses on the development, manufacturing, and commercialization of in-vitro diagnostic (IVD) products for the detection of various infectious diseases. Research and development activities include the creation of rapid tests, PCR-based assays, and chemiluminescence immunoassays (CLIA) for pathogens such as influenza, respiratory syncytial virus (RSV), and emerging threats like Chikungunya. Technologies employed include colloidal gold, up-conversion luminescence, and microfluidic platforms. The segment addresses the need for accurate and timely diagnosis, enabling effective patient management and public health interventions. Market positioning emphasizes innovation, accuracy, and ease of use, with a focus on both professional and point-of-care settings. Future opportunities include expansion into new disease areas, development of multiplexed assays, and integration with digital health platforms. Regulatory and clinical aspects involve rigorous testing and validation to meet international standards. Partnerships with healthcare providers and public health organizations are crucial for market access and distribution.

This segment is dedicated to the research, development, and production of diagnostic products for drug detection. The company utilizes technologies such as colloidal gold and other immunoassay techniques to create rapid tests and screening tools. These products are designed for various applications, including workplace drug testing, public safety, and clinical settings. The segment addresses the need for accurate and reliable drug screening, contributing to safer environments and assisting in substance abuse management. Market positioning focuses on providing cost-effective and user-friendly solutions. Future opportunities include expanding the range of detectable substances and integrating these tests with digital platforms for data management and reporting. Regulatory compliance and adherence to industry standards are critical aspects of this segment. Partnerships with testing laboratories and government agencies are essential for market penetration and distribution.

This segment focuses on the development and commercialization of antibody-based medicines. Research and development activities include the discovery and characterization of antibodies for therapeutic applications. The company leverages its expertise in biotechnology to develop innovative antibody-based therapies for various diseases. This segment addresses the need for targeted and effective treatments, particularly in areas with unmet medical needs. Market positioning emphasizes the development of high-quality antibody medicines with strong efficacy and safety profiles. Future opportunities include expanding the pipeline of antibody-based therapies and exploring new therapeutic areas. Regulatory and clinical aspects involve rigorous testing and validation to meet international standards. Partnerships with pharmaceutical companies and research institutions are crucial for clinical development and commercialization.